organization · Reporting owner
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHINA JO-JO DRUGSTORES, INC.CJJD · Entity 162163 | 10% owner | January 19, 2017 | January 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHINA JO-JO DRUGSTORES, INC.
Report date January 19, 2017 · Filed January 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee footnote | 4,840,000 |
Reported balance
Holding disclosure · report date 2017-01-19 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,840,000 F1: The securities to which this filing relates are held directly by CareRetail Holdings Limited, an exempt company incorporated under the laws of the Cayman Islands.Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person"), has sole investment power and voting power over the securities held by CareRetail Holdings Limited. Mr. Lei Zhang may be deemed to have controlling power over Hillhouse Capital. Mr. Lei Zhang disclaims beneficial ownership of all of the shares held by CareRetail Holdings Limited, except to the extent of his pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities to which this filing relates are held directly by CareRetail Holdings Limited, an exempt company incorporated under the laws of the Cayman Islands.Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person"), has sole investment power and voting power over the securities held by CareRetail Holdings Limited. Mr. Lei Zhang may be deemed to have controlling power over Hillhouse Capital. Mr. Lei Zhang disclaims beneficial ownership of all of the shares held by CareRetail Holdings Limited, except to the extent of his pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apellis Pharmaceuticals, Inc.
Report date November 13, 2017 · Filed November 15, 2017
Section 16 reporting ended · disclosed 2017-11-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 2,098,581 |
Reported balance
After 2017-11-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-11-13 · Conversion · Acquired 2,098,581 · Balance 2,098,581 F1: The Series D Convertible Preferred Stock was convertible at any time, at the holder's election, into shares of the Issuer's common stock, $0.0001 par value ("Common Stock") on a 2.133-for-1 basis. The Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 2.133-for-1 basis upon the closing of the Issuer's initial public offering. The Series D Convertible Preferred Stock did not have an expiration date. F2: The securities reported on this line are held directly by Hillhouse WHP Holdings Limited, a company incorporated under the laws of the British Virgin Islands ("WHP"). WHP is owned by Hillhouse Fund II, L.P., a Cayman Islands limited partnership ("Fund II"). F4: Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person") acts as the sole management company of Fund II and Gaoling and the sole general partner of YHG. Hillhouse Capital is deemed to be the sole beneficial owner of, and to control the investment and voting power of, the securities held by the Hillhouse Entities. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or other wise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,527,152 |
Reported balance
After 2017-11-13 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-11-13 · Purchase · Acquired 1,428,571 · Balance 3,527,152 F3: The securities reported on this line are held directly by (i) Gaoling Fund, L.P., an exempted Cayman Islands limited partnership ("Gaoling") and (ii) YHG Investment, L.P., an exempted Cayman limited partnership ("YHG" and together with WHP and Gaoling, the "Hillhouse Entities"). F4: Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person") acts as the sole management company of Fund II and Gaoling and the sole general partner of YHG. Hillhouse Capital is deemed to be the sole beneficial owner of, and to control the investment and voting power of, the securities held by the Hillhouse Entities. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or other wise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2017-11-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-13 · Conversion · Acquired 4,476,275 · Balance 0 F1: The Series D Convertible Preferred Stock was convertible at any time, at the holder's election, into shares of the Issuer's common stock, $0.0001 par value ("Common Stock") on a 2.133-for-1 basis. The Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 2.133-for-1 basis upon the closing of the Issuer's initial public offering. The Series D Convertible Preferred Stock did not have an expiration date. F2: The securities reported on this line are held directly by Hillhouse WHP Holdings Limited, a company incorporated under the laws of the British Virgin Islands ("WHP"). WHP is owned by Hillhouse Fund II, L.P., a Cayman Islands limited partnership ("Fund II"). F4: Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person") acts as the sole management company of Fund II and Gaoling and the sole general partner of YHG. Hillhouse Capital is deemed to be the sole beneficial owner of, and to control the investment and voting power of, the securities held by the Hillhouse Entities. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or other wise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series D Convertible Preferred Stock was convertible at any time, at the holder's election, into shares of the Issuer's common stock, $0.0001 par value ("Common Stock") on a 2.133-for-1 basis. The Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 2.133-for-1 basis upon the closing of the Issuer's initial public offering. The Series D Convertible Preferred Stock did not have an expiration date.
F2: The securities reported on this line are held directly by Hillhouse WHP Holdings Limited, a company incorporated under the laws of the British Virgin Islands ("WHP"). WHP is owned by Hillhouse Fund II, L.P., a Cayman Islands limited partnership ("Fund II").
F3: The securities reported on this line are held directly by (i) Gaoling Fund, L.P., an exempted Cayman Islands limited partnership ("Gaoling") and (ii) YHG Investment, L.P., an exempted Cayman limited partnership ("YHG" and together with WHP and Gaoling, the "Hillhouse Entities").
F4: Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person") acts as the sole management company of Fund II and Gaoling and the sole general partner of YHG. Hillhouse Capital is deemed to be the sole beneficial owner of, and to control the investment and voting power of, the securities held by the Hillhouse Entities. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or other wise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
ArriVent BioPharma, Inc.
Report date December 10, 2025 · Filed February 03, 2026
Jointly reported with HHLR ADVISORS, LTD.
Section 16 reporting ended · disclosed 2026-02-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,929,117 |
Reported balance
After 2025-12-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-10 · Sale · Disposed 555,555 · Balance 3,929,117 F1: The securities reported herein were held by HACF, L.P., an exempted Cayman Islands limited partnership ("HACF"). HHLR (as defined below) acts as the sole management company of HACF. F2: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Venture Fund V"), VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). HIM (as defined below) acts as the sole management company of each of Venture Fund V, Healthcare Fund and Venture Fund VI. F3: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F4: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein were held by HACF, L.P., an exempted Cayman Islands limited partnership ("HACF"). HHLR (as defined below) acts as the sole management company of HACF.
F2: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Venture Fund V"), VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). HIM (as defined below) acts as the sole management company of each of Venture Fund V, Healthcare Fund and Venture Fund VI.
F3: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly.
F4: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
BeOne Medicines Ltd.
Report date December 02, 2024 · Filed December 04, 2024
Jointly reported with HHLR ADVISORS, LTD.
Section 16 reporting ended · disclosed 2024-12-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 125,045,741 |
Reported balance
After 2024-12-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-12-02 · Sale · Disposed 17,842,500 · Balance 125,045,741 F1: The ordinary shares, par value $0.0001 per share ("Ordinary Shares") sold were in the form of American Depositary Shares ("ADSs"). The reported price is the price of each ADS sold; the price was paid in USD. Each ADS represents 13 Ordinary Shares. F2: Consists of (i) 111,597,423 Ordinary Shares held by funds managed by HHLR (as defined below), of which 36,011,300 Ordinary Shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 Ordinary Shares held by a fund managed by HIM (as defined below), of which 13,445,978 Ordinary Shares are held in the form of 1,034,306 ADSs. F3: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"), and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F4: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares, par value $0.0001 per share ("Ordinary Shares") sold were in the form of American Depositary Shares ("ADSs"). The reported price is the price of each ADS sold; the price was paid in USD. Each ADS represents 13 Ordinary Shares.
F2: Consists of (i) 111,597,423 Ordinary Shares held by funds managed by HHLR (as defined below), of which 36,011,300 Ordinary Shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 Ordinary Shares held by a fund managed by HIM (as defined below), of which 13,445,978 Ordinary Shares are held in the form of 1,034,306 ADSs.
F3: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"), and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly.
F4: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
Enfusion, Inc.
Report date October 25, 2021 · Filed October 27, 2021
Section 16 reporting ended · disclosed 2021-10-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee footnote | 4,975,183 |
Reported balance
After 2021-10-25 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-10-25 · Sale · Disposed 647,862 · Balance 4,975,183 F1: Represents shares of Class A Common Stock sold to the underwriters in the issuer's initial public offering. F2: The securities to which this filing relates are held directly by ELL Investments, L.P. ("ELL"), a wholly owned subsidiary of Hillhouse Fund IV, L.P. ("Fund IV"). Hillhouse Investment Management, Ltd. (the "Reporting Person") acts as the sole management company of Fund IV and as such may be deemed to be the beneficial owner of, and to control the voting power of, the shares of Class A common stock held by ELL. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Class A Common Stock sold to the underwriters in the issuer's initial public offering.
F2: The securities to which this filing relates are held directly by ELL Investments, L.P. ("ELL"), a wholly owned subsidiary of Hillhouse Fund IV, L.P. ("Fund IV"). Hillhouse Investment Management, Ltd. (the "Reporting Person") acts as the sole management company of Fund IV and as such may be deemed to be the beneficial owner of, and to control the voting power of, the shares of Class A common stock held by ELL. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2025 Filed Feb 3, 2026 21:05 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | SaleCommon Stock | 555,555 | $23.37 | $12,983,320.35 |
DisclosureSEC source: 0000902664-26-000675 · ownership.xml · nonDerivative · entry 1 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,929,117 F1 · shares: The securities reported herein were held by HACF, L.P., an exempted Cayman Islands limited partnership ("HACF"). HHLR (as defined below) acts as the sole management company of HACF. F2 · balance_after: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Venture Fund V"), VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). HIM (as defined below) acts as the sole management company of each of Venture Fund V, Healthcare Fund and Venture Fund VI. F3 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 17,842,500 | $200.00 | $3,568,500,000.00 |
DisclosureSEC source: 0000902664-24-006828 · ownership.xml · nonDerivative · entry 1 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 125,045,741 F1 · price: The ordinary shares, par value $0.0001 per share ("Ordinary Shares") sold were in the form of American Depositary Shares ("ADSs"). The reported price is the price of each ADS sold; the price was paid in USD. Each ADS represents 13 Ordinary Shares. F2 · balance_after: Consists of (i) 111,597,423 Ordinary Shares held by funds managed by HHLR (as defined below), of which 36,011,300 Ordinary Shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 Ordinary Shares held by a fund managed by HIM (as defined below), of which 13,445,978 Ordinary Shares are held in the form of 1,034,306 ADSs. F3 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"), and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F4 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:47 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | ConversionSeries B Preferred Stock · Derivative | 4,761,903 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-24-000903 · ownership.xml · derivative · entry 5 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 313,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F3 · shares: The securities reported herein are held by VSUM VIII and ARVT Holdings Limited ("ARVT"). VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Hillhouse Venture VI"). HIM acts as the sole management company of each of Hillhouse Healthcare and Hillhouse Venture VI. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:47 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | ConversionSeries A Preferred Stock · Derivative | 55,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-24-000903 · ownership.xml · derivative · entry 4 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,616,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F2 · shares: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI") and VSUM VIII Holdings Limited ("VSUM VIII"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Hillhouse Venture V") and VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Hillhouse Healthcare"). HIM (as defined below) acts as the sole management company of each of Hillhouse Venture V and Hillhouse Healthcare. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:47 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | PurchaseCommon Stock | 555,555 | $18.00 | $9,999,990.00 |
DisclosureSEC source: 0000902664-24-000903 · ownership.xml · nonDerivative · entry 3 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 4,484,672 F4 · shares: The securities reported herein are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"). HHLR (as defined below) acts as the sole management company of HHLR Fund. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:47 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | ConversionCommon Stock | 313,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-24-000903 · ownership.xml · nonDerivative · entry 2 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,929,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI") and VSUM VIII Holdings Limited ("VSUM VIII"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Hillhouse Venture V") and VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Hillhouse Healthcare"). HIM (as defined below) acts as the sole management company of each of Hillhouse Venture V and Hillhouse Healthcare. F3 · shares: The securities reported herein are held by VSUM VIII and ARVT Holdings Limited ("ARVT"). VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Hillhouse Venture VI"). HIM acts as the sole management company of each of Hillhouse Healthcare and Hillhouse Venture VI. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:47 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | ConversionCommon Stock | 3,616,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-24-000903 · ownership.xml · nonDerivative · entry 1 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,616,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI") and VSUM VIII Holdings Limited ("VSUM VIII"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Hillhouse Venture V") and VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Hillhouse Healthcare"). HIM (as defined below) acts as the sole management company of each of Hillhouse Venture V and Hillhouse Healthcare. F3 · shares: The securities reported herein are held by VSUM VIII and ARVT Holdings Limited ("ARVT"). VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Hillhouse Venture VI"). HIM acts as the sole management company of each of Hillhouse Healthcare and Hillhouse Venture VI. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 23:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 273,728 | $207.72 | $56,857,986.35 |
DisclosureSEC source: 0000902664-23-003603 · ownership.xml · nonDerivative · entry 3 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 142,888,241 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F4 · balance_after: Consists of (i) 129,439,923 ordinary shares held by funds managed by HHLR (as defined below), of which 53,853,800 ordinary shares are held in the form of 4,142,600 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM (as defined below), of which 13,445,978 ordinary shares are held in the form of 1,034,306 ADSs. F5 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F6 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 23:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 313,400 | $128.43 | $40,251,058.90 |
DisclosureSEC source: 0000902664-23-003603 · ownership.xml · nonDerivative · entry 2 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 143,161,969 F2 · price: The ordinary shares were sold through the Stock Exchange of Hong Kong, the price was paid in HKD. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from HKD127.75 to HKD128.5985, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ordinary shares sold at each separate price. F5 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F6 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 23:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 611,000 | $211.45 | $129,197,294.20 |
DisclosureSEC source: 0000902664-23-003603 · ownership.xml · nonDerivative · entry 1 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 143,475,369 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F5 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F6 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 01:57 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 968,812 | $213.91 | $207,240,996.95 |
DisclosureSEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 5 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 144,086,369 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F5 · balance_after: Consists of (i) 130,638,051 ordinary shares held by funds managed by HHLR (as defined below), of which 54,737,800 ordinary shares are held in the form of 4,210,600 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM (as defined below), of which 13,445,978 ordinary shares are held in the form of 1,034,306 ADSs. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 01:57 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 281,400 | $130.83 | $36,816,181.08 |
DisclosureSEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 4 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 145,055,181 F2 · price: The ordinary shares were sold through the Stock Exchange of Hong Kong, the price was paid in HKD. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from HKD131.7943 to HKD131.0298 inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ordinary shares sold at each separate price. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 01:57 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 328,952 | $217.02 | $71,388,603.82 |
DisclosureSEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 3 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 145,336,581 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 01:57 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 213,700 | $130.35 | $27,856,286.51 |
DisclosureSEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 2 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 145,665,533 F2 · price: The ordinary shares were sold through the Stock Exchange of Hong Kong, the price was paid in HKD. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from HKD130.2787 to HKD130.550, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ordinary shares sold at each separate price. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:57 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 1,163,825 | $218.14 | $253,881,789.95 |
DisclosureSEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 1 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 145,879,233 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:15 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | OtherOrdinary Shares | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-22-004100 · ownership.xml · nonDerivative · entry 1 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 147,043,058 F1 · kind: Represents a transfer of shares by Qingqing Yi ("Mr. Yi"), a director of the Issuer and an employee of the Reporting Persons (as defined below), to certain funds managed by the Reporting Persons and for whose benefit he was holding the shares. The Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. F2 · balance_after: Consists of (i) 133,594,740 ordinary shares held by funds managed by HHLR (as defined below), of which 127,971,155 ordinary shares are held in the form of 9,843,935 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM (as defined below), of which 13,447,603 ordinary shares are held in the form of 1,034,431 ADSs. F3 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F4 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 16:20 UTC | Enfusion, Inc. ENFN · Entity 80590 | SaleClass A common stock, par value $0.001 per share | 647,862 | $15.90 | $10,297,766.49 |
DisclosureSEC source: 0000902664-21-004622 · ownership.xml · nonDerivative · entry 1 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,975,183 F1 · shares: Represents shares of Class A Common Stock sold to the underwriters in the issuer's initial public offering. F2 · ownership.nature: The securities to which this filing relates are held directly by ELL Investments, L.P. ("ELL"), a wholly owned subsidiary of Hillhouse Fund IV, L.P. ("Fund IV"). Hillhouse Investment Management, Ltd. (the "Reporting Person") acts as the sole management company of Fund IV and as such may be deemed to be the beneficial owner of, and to control the voting power of, the shares of Class A common stock held by ELL. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 21:32 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | ConversionSeries D Convertible Preferred Stock · Derivative | 4,476,275 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-17-004362 · p17-2141form4.xml · derivative · entry 3 Hillhouse Capital Management, Ltd. · CIK 0001510589 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,098,581 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series D Convertible Preferred Stock was convertible at any time, at the holder's election, into shares of the Issuer's common stock, $0.0001 par value ("Common Stock") on a 2.133-for-1 basis. The Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 2.133-for-1 basis upon the closing of the Issuer's initial public offering. The Series D Convertible Preferred Stock did not have an expiration date. F1 · derivative.exercise_date: The Series D Convertible Preferred Stock was convertible at any time, at the holder's election, into shares of the Issuer's common stock, $0.0001 par value ("Common Stock") on a 2.133-for-1 basis. The Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 2.133-for-1 basis upon the closing of the Issuer's initial public offering. The Series D Convertible Preferred Stock did not have an expiration date. F1 · derivative.expiration_date: The Series D Convertible Preferred Stock was convertible at any time, at the holder's election, into shares of the Issuer's common stock, $0.0001 par value ("Common Stock") on a 2.133-for-1 basis. The Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 2.133-for-1 basis upon the closing of the Issuer's initial public offering. The Series D Convertible Preferred Stock did not have an expiration date. F2 · ownership.nature: The securities reported on this line are held directly by Hillhouse WHP Holdings Limited, a company incorporated under the laws of the British Virgin Islands ("WHP"). WHP is owned by Hillhouse Fund II, L.P., a Cayman Islands limited partnership ("Fund II"). F4 · ownership.nature: Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person") acts as the sole management company of Fund II and Gaoling and the sole general partner of YHG. Hillhouse Capital is deemed to be the sole beneficial owner of, and to control the investment and voting power of, the securities held by the Hillhouse Entities. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or other wise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 21:32 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 1,428,571 | $14.00 | $19,999,994.00 |
DisclosureSEC source: 0000902664-17-004362 · p17-2141form4.xml · nonDerivative · entry 2 Hillhouse Capital Management, Ltd. · CIK 0001510589 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 3,527,152 F3 · ownership.nature: The securities reported on this line are held directly by (i) Gaoling Fund, L.P., an exempted Cayman Islands limited partnership ("Gaoling") and (ii) YHG Investment, L.P., an exempted Cayman limited partnership ("YHG" and together with WHP and Gaoling, the "Hillhouse Entities"). F4 · ownership.nature: Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person") acts as the sole management company of Fund II and Gaoling and the sole general partner of YHG. Hillhouse Capital is deemed to be the sole beneficial owner of, and to control the investment and voting power of, the securities held by the Hillhouse Entities. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or other wise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 21:32 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | ConversionCommon Stock | 2,098,581 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-17-004362 · p17-2141form4.xml · nonDerivative · entry 1 Hillhouse Capital Management, Ltd. · CIK 0001510589 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,098,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series D Convertible Preferred Stock was convertible at any time, at the holder's election, into shares of the Issuer's common stock, $0.0001 par value ("Common Stock") on a 2.133-for-1 basis. The Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 2.133-for-1 basis upon the closing of the Issuer's initial public offering. The Series D Convertible Preferred Stock did not have an expiration date. F2 · ownership.nature: The securities reported on this line are held directly by Hillhouse WHP Holdings Limited, a company incorporated under the laws of the British Virgin Islands ("WHP"). WHP is owned by Hillhouse Fund II, L.P., a Cayman Islands limited partnership ("Fund II"). F4 · ownership.nature: Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("Hillhouse Capital" or the "Reporting Person") acts as the sole management company of Fund II and Gaoling and the sole general partner of YHG. Hillhouse Capital is deemed to be the sole beneficial owner of, and to control the investment and voting power of, the securities held by the Hillhouse Entities. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or other wise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.